CTLA4 and neoplasm: The use of ICIs, such as those targeting programmed death 1 (PD-1), programmed death-ligand 1(PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), blocks the interaction between tumour tissues and T cells, thereby restoring normal immune function and providing significant survival benefits to patients (12).